Physician profile
Mark C Nolan
NPI 1871559211
$6,068.35
in general payments reported to CMS, 2019-2025
14 companies · $3,975 in 2025
The $3,975 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $86.25 · 2021: $160 · 2022: $435 · 2023: $611 · 2024: $321 · 2025: $3,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,894 · Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,894.01 |
| Food and Beverage | $2,012.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,942.15 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens |
| Biotissue Holdings INC. | $466.33 | 2023-2024 | |
| Alcon Vision LLC | $382.50 | 2019-2023 | Clareon |
| Bausch & Lomb Americas INC. | $249.31 | 2023 | Miebo, Vyzulta |
| Allergan, INC. | $244.88 | 2022 | |
| Lombart Brothers, INC. | $171.93 | 2019-2020 | |
| Dompe US, INC. | $159.55 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $148.53 | 2025 | |
| Sun Pharmaceutical Industries INC. | $93.39 | 2019 | |
| Shire North American Group INC | $81.45 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $51.08 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.31 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.32 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $15.62 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.